Quarterly ResultApr 30, 2026, 04:33 PM
BIO Net Loss $(527.1)M; EPS $(19.55) on Sartorius Investment Loss
AI Summary
BIO-RAD LABORATORIES, INC. reported a net loss of $(527.1) million, or $(19.55) per basic share, for the three months ended March 31, 2026, a significant decline from a net income of $64.0 million in the prior year. This loss was primarily driven by a $738.2 million loss from the change in fair market value of equity securities, largely related to its investment in Sartorius AG. Despite the net loss, net sales increased slightly to $592.1 million from $585.4 million year-over-year, and income from operations improved to $34.1 million. Total assets decreased to $9,790.0 million from $10,576.5 million since December 31, 2025.
Key Highlights
- Net loss of $(527.1)M in Q1 2026, compared to net income of $64.0M in Q1 2025.
- Basic EPS was $(19.55) in Q1 2026, down from $2.29 in Q1 2025.
- Reported a $738.2M loss from fair value change of equity securities, mainly Sartorius AG.
- Net sales increased to $592.1M in Q1 2026, up from $585.4M in Q1 2025.
- Income from operations rose to $34.1M in Q1 2026, from $23.7M in Q1 2025.
- Net cash provided by operating activities was $108.1M in Q1 2026.
- Purchased $47.8M of treasury stock in Q1 2026.
- Total assets decreased to $9,790.0M from $10,576.5M since Dec 31, 2025.